SuperworthEstablishment Labs ESTA
- Market cap
- $1.9B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 7.7×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $245.8M
- +39% on a year ago
- Net margin
- −15.8%
- Free cash flow yield
- −2.2%
Establishment Labs trades at 7.7× sales. Its trailing earnings are negative, so it has no PE. Revenue was $245.8M over the last twelve months, up 39% on a year earlier with a −16% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $38.5M+1% | $31.6M−28% | $37.2M−20% | $44.1M−9% | $40.2M+5% | $44.5M+41% | $41.4M+11% | $51.3M+16% | $53.8M+34% | $64.6M+45% | $59.9M+45% | $67.5M+32% | |
| Cost of revenue | $12.5M+2% | $11M−30% | $12.8M−22% | $15.2M−17% | $14.5M+17% | $14M+28% | $13.6M+6% | $16M+6% | $16.1M+11% | $19.1M+36% | $17.5M+29% | $19.8M+24% |
| Gross profit | $26.1M+0% | $20.6M−27% | $24.4M−19% | $28.9M−4% | $25.7M−1% | $30.5M+48% | $27.8M+14% | $35.3M+22% | $37.7M+47% | $45.5M+49% | $42.3M+52% | $47.7M+35% |
| R&D | $7.1M+35% | $5.8M−10% | $4.3M−35% | $5.5M−21% | $4.8M−33% | $5.1M−12% | $5.1M+18% | $5.2M−5% | $4.6M−5% | $5.4M+6% | $5.2M+4% | $5.1M−2% |
| SG&A | $40M+28% | $36.9M+6% | $28.9M−9% | $32.8M−11% | $34.1M−15% | $44M+19% | $39.7M+37% | $44.2M+35% | $37.2M+9% | $44M+0% | $43.6M+10% | $46.9M+6% |
| −$21M+100% | −$22.1M+68% | −$8.8M+8% | −$9.3M−32% | −$13.1M−38% | −$18.7M−16% | −$16.9M+92% | −$14.1M+51% | −$4M−69% | −$3.9M−79% | −$6.5M−62% | −$4.3M−70% | |
| Interest expense | $3.7M−5% | $4.3M+97% | $4.4M+17% | $5.2M+43% | $5.3M+44% | $5.9M+37% | $5.9M+34% | $6M+15% | $6.2M+17% | $7.2M+22% | $7.1M+21% | $7M+18% |
| Pre-tax income | −$28.6M+59% | −$23M+81% | −$15.8M+42% | −$16.8M+6% | −$16.2M−44% | −$35.9M+56% | −$19.8M+26% | −$15.6M−7% | −$10.7M−34% | −$11.9M−67% | −$13.1M−34% | −$11.7M−25% |
| $669K+11% | −$2.5M | $438K−47% | $428K−54% | $510K−24% | −$1.4M−44% | $914K+109% | $1M+135% | $424K−17% | −$9.3M+561% | $288K−69% | $6K−99% | |
| Net income | −$29.3M+57% | −$20.5M+52% | −$16.2M+36% | −$17.2M+3% | −$16.7M−43% | −$34.5M+68% | −$20.7M+28% | −$16.6M−3% | −$11.1M−33% | −$2.6M−92% | −$13.4M−35% | −$11.7M−29% |
| −$1.12+47% | −$0.79+44% | −$0.58+21% | −$0.62−5% | −$0.59−47% | −$1.19+51% | −$0.70+21% | −$0.57−8% | −$0.38−36% | −$0.09−92% | −$0.45−36% | −$0.39−32% | |
| 26M+6% | 26.1M+6% | 27.8M+13% | 27.9M+9% | 28.2M+9% | 29M+11% | 29.5M+6% | 28.9M+4% | 29.6M+5% | 29.8M+3% | 29.9M+2% | 30.1M+4% |
Revenue: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
R&D: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
SG&A: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Operating income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Income tax: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Net income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
EPS, diluted: 11 periods, Q1 FY17 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY17: share-days: the 6-month average less the second quarter's. 9 periods, Q4 FY17 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Establishment Labs' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ESTAEstablishment Labs | $1.9B | n/m | n/a | 7.7× | +39% | −15.8% | |
| LMATLemaitre Vascular | $1.9B | 29.6× | 42.0× | 7.4× | +12% | 25.0% | |
| INSPInspire Medical Systems | $2.1B | 15.4× | 58.0× | 2.3× | +4% | 15.0% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| ATRCAtriCure | $3B | 281× | 58.4× | 5.3× | +14% | 1.9% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| WRBYWarby Parker | $3.2B | 370× | 366× | 3.5× | +11% | 0.8% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| Peer median | $1.7B | 34.4× | 47.7× | 3.4× | +11% | 7.3% |
Investors who own it
Investors we follow who held Establishment Labs at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.0% of portfoliotrimmed
- Polen CapitalPolen Capital0.0% of portfoliotrimmed
More on Establishment Labs
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .